EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells

Cancer Investigation

Volumn 27, Issue 1, 2009, Pages 29-37

  Luo, Wenjing ^a   Chen, Yaoming ^a   Liu, Mingchao ^a   Du, Kejun ^a   Zheng, Gang ^a   Cai, Tongjian ^a   Zhang, Wenbin ^a   Zhao, Fang ^a   Yao, Ting ^a   Yang, Ruihua ^a   Chen, Jingyuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; EB1089; Human hepatoma cancer; p27; Skp2

Indexed keywords

PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN; SEOCALCITOL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CALCITRIOL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 60549115637     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802438569     Document Type: Article

References (35)

1. Hansen, C.M.; Hamberg, K.J.; Binderup, E.; Binderup, L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 2000, 6(7), 803-828.
2. Bernardi, R.J.; Johnson, C.S.; Modzelewski, R.A.; Trump, D.L. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinol 2002, 143(7), 2508-2514.
3. Ordonez-Moran, P; Larriba, M.J.; Pendas-Franco, N.; Aguilera, O.; Gonzalez-Sancho, J.M.; Munoz, A. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 2005, 10, 2723-2749.
4. Fernandez-Garcia, N.I.; Palmer, H.G.; Garcia, M.; Gonzalez-Martin, A.; del Rio, M.; Barettino, D.; et al. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 2005, 24(43), 6533-6544.
5. Hoyer-Hansen, M.; Bastholm, L.; Mathiasen, I.S.; Elling, F.; Jaattela, M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ 2005, 12(10), 1297-1309.
6. Chen, T.C.; Holick, M.F.; Lokeshwar, B.L.; Burnstein, K.L.; Schwartz, G.G. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003, 164, 273-288.
7. Takahashi, H.; Ibe, M.; Kinouchi, M.; Ishida-Yamamoto, A.; Hashimoto, Y.; Iizuka, H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003, 31(1), 21-28.
8. Stio, M.; Bonanomi, A.G.; d'Albasio, G.; Treves, C. Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 2001, 61(3), 365-371.
9. Milliken, E.L.; Zhang, X.; Flask, C.; Duerk, J.L.; MacDonald, P.N.; Keri, R.A. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett 2005, 229(2), 205-215.
10. Valrance, M.E.; Welsh, J. Breast cancer cell regulation by high-dose Vitamin D compounds in the absence of nuclear vitamin D receptor. J. Steroid Biochem. Mol Biol 2004, 89-90(1-5), 221-225.
11. Pagano, M.; Tam, S.W.; Theodoras, A.M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269(5224), 682-685.
12. Chen, T.P.; Chen, C.M.; Chang, H.W.; Wang, J.S.; Chang, W.C.; Hsu, S.I.; et al. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol 2007, 104(3), 516-523.
13. Wang, C.; Hou, X.; Mohapatra, S.; Ma, Y.; Cress, W.D.; Pledger, W.J.; et al. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem 2005, 280(13), 12339-12343.
14. Huang, C.; Ma, W.; Ding, M.; Bowden, G.T.; Dong, Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J Biol Chem 1997, 272(44), 27753-27757.
15. Ouyang, W.; Ma, Q.; Li, J.; Zhang, D.; Liu, Z.G.; Rustgi, A.K.; et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005, 65(20), 9287-9293.
16. Blain, S.W.; Scher, H.I.; Cordon-Cardo, C.; Koff, A. p27 as a target for cancer therapeutics. Cancer Cell 2003, 3(2), 111-115.
17. Carrano, A.C.; Eytan, E.; Hershko, A.; Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Bio 1999, 1(4), 193-199.
18. Sutterluty, H.; Chatelain, E.; Marti, A.; et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol 1999, 1(4), 207-214.
19. Wang, Q.M.; Jones, J.B.; Studzinski, G.P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996, 56(2), 264-267.
20. Li, P.; Li, C.; Zhao, X.; Zhang, X.; Nicosia, S.V.; Bai, W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/ Skp2 ubiquitin ligase. J Biol Chem 2004, 279(24), 25260-25267.
21. Flynn, G.; Chung, I.; Yu, W.D.; Romano, M.; Modzelewski, R.A.; Johnson, C.S.; et al. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncol 2006, 70(6), 447-457.
22. Gedlicka, C.; Hager, G.; Weissenbock, M.; Gedlicka, W.; Knerer, B.; Kornfehl, J.; et al. 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 2006, 35(8), 472-478.
23. Alagbala, A.A.; Johnson, C.S.; Trump, D.L.; Posner, G.H.; Foster, B.A. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Oncol 2006, 70(6), 483-492.
24. Lin, R.; Wang, T.T.; Miller, W.H. Jr.; White, J.H. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinol 2003, 144(3), 749-753.
25. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nature Rev 2001, 1(3), 222-231.
26. Fero, M.L.; Randel, E.; Gurley, K.E.; Roberts, J.M.; Kemp, C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396(6707), 177-180.
27. Baldassarre, G.; Belletti, B.; Bruni, P.; Boccia, A.; Trapasso, F.; Pentimalli, F.; et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999, 104(7), 865-874.
28. Kullmann, M.; Gopfert, U.; Siewe, B.; Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes & Dev 2002, 16(23), 3087-3099.
29. Pumiglia, K.M.; Decker, S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(2), 448-452.
30. Spruck, C.; Strohmaier, H.; Watson, M.; Smith, A.P.; Ryan, A.; Krek, T.W.; et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Molecular Cell 2001, 7(3), 639-650.
31. Tsvetkov, L.M.; Yeh, K.H.; Lee, S.J.; Sun, H.; Zhang, H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999 Jun 17, 9(12), 661-664.
32. Gstaiger, M.; Jordan, R.; Lim, M.; Catzavelos, C.; Mestan, J.; Slingerland, J.; et al. Skp2 is oncogenic and overexpressed in human cancers. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(9), 5043-5048.
33. Kudo, Y.; Kitajima, S.; Sato, S.; Miyauchi, M.; Ogawa, I.; Takata, T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001, 61(19), 7044-7047.
34. Lu, L.; Schulz, H.; Wolf, D.A. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Bio 2002, 20(3), 22.
35. Latres, E.; Chiarle, R.; Schulman, B.A.; Pavletich, N.P.; Pellicer, A.; Inghirami, G.; et al. Role of the F-box protein Skp2 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(5), 2515-2520.